Metabolism in Huntington's disease: a major contributor to pathology
- PMID: 34704220
- DOI: 10.1007/s11011-021-00844-y
Metabolism in Huntington's disease: a major contributor to pathology
Abstract
Huntington's disease (HD) is a progressively debilitating neurodegenerative disease exhibiting autosomal-dominant inheritance. It is caused by an unstable expansion in the CAG repeat tract of HD gene, which transforms the disease-specific Huntingtin protein (HTT) to a mutant form (mHTT). The profound neuronal death in cortico-striatal circuits led to its identification and characterisation as a neurodegenerative disease. However, equally disturbing are the concomitant whole-body manifestations affecting nearly every organ of the diseased individuals, at varying extents. Altered central and peripheral metabolism of energy, proteins, nucleic acids, lipids and carbohydrates encompass the gross pathology of the disease. Intense fluctuation of body weight, glucose homeostasis and organ-specific subcellular abnormalities are being increasingly recognised in HD. Many of these metabolic abnormalities exist years before the neuropathological manifestations such as chorea, cognitive decline and behavioural abnormalities develop, and prove to be reliable predictors of the disease progression. In this review, we provide a consolidated overview of the central and peripheral metabolic abnormalities associated with HD, as evidenced from clinical and experimental studies. Additionally, we have discussed the potential of metabolic biomolecules to translate into efficient biomarkers for the disease onset as well as progression. Finally, we provide a brief outlook on the efficacy of existing therapies targeting metabolic remediation. While it is clear that components of altered metabolic pathways can mark many aspects of the disease, it is only conceivable that combinatorial therapies aiming for neuronal protection in consort with metabolic upliftment will prove to be more efficient than the existing symptomatic treatment options.
Keywords: Biomarker potential; Huntington’s disease; Metabolic dysfunction; Neurodegeneration; Peripheral tissues; Therapeutics.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Aditi K, Shakarad MN, Agrawal N (2016) Altered lipid metabolism in Drosophila model of Huntington’s disease. Sci Rep 6:31411. https://doi.org/10.1038/srep31411 - DOI - PubMed - PMC
-
- Aldaz T, Nigro P, Sánchez-Gómez A et al (2019) Non-motor symptoms in Huntington’s disease: a comparative study with Parkinson’s disease. J Neurol 266:1340–1350. https://doi.org/10.1007/s00415-019-09263-7 - DOI - PubMed
-
- Andersen JV, Skotte NH, Aldana BI et al (2019) Enhanced cerebral branched-chain amino acid metabolism in R6/2 mouse model of Huntington’s disease. Cell Mol Life Sci 76:2449–2461. https://doi.org/10.1007/s00018-019-03051-2 - DOI - PubMed
-
- Andreassen OA, Dedeoglu A, Stanojevic V et al (2002) Huntington’s disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 11:410–424. https://doi.org/10.1006/nbdi.2002.0562 - DOI - PubMed
-
- Andrich J, Schmitz T, Saft C et al (2002) Autonomic nervous system function in Huntington’s disease. J Neurol Neurosurg Psychiatry 72:726–731. https://doi.org/10.1136/jnnp.72.6.726 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical